Table 1 |
||||||
|
Serum heterotrimer, BLyS, and APRIL levels in healthy donors, and patients with SLE or RA |
||||||
|
Heterotrimer |
BLyS |
APRIL |
||||
|
|
|
|
||||
|
Patients |
Number of samples with > LOQ n/N (%) |
Mean ± SDa (ng/ml) |
Number of samples with > LOQ n/N (%) |
Mean ± SDa (ng/ml) |
Number of samples with > LOQ n/N (%) |
Mean ± SDa (ng/ml) |
|
|
||||||
|
Healthy donors |
7/89 (7.8) |
0.83 ± 0.61 |
7/40 (17.5) |
3.91 ± 3.47 |
1/39 (2.6)b |
2.35 ± 0 |
|
SLE |
24/89 (26.9) |
0.52 ± 0.19 |
20/30 (66.7) |
3.28 ± 2.35 |
11/29 (37.9)b |
2.31 ± 0.18 |
|
RA |
2/30 (6.7) |
2.85 ± 3.55 |
10/30 (33.3) |
8.07 ± 18.0 |
25/30 (83.3) |
3.15 ± 1.44 |
|
|
||||||
|
aMean concentration for serum samples with detectable ligand levels. bIn the subset of serum samples available, one sample from a healthy donor and one from a patient with SLE were not assayed because of insufficient volume. LOQ, limit of quantitation; RA, rheumatoid arthritis; SD, standard deviation; SLE, systemic lupus erythematosus. |
||||||
|
Dillon et al. Arthritis Research & Therapy 2010 12:R48 doi:10.1186/ar2959 |
||||||
